cetuximab


Also found in: Medical, Wikipedia.

cetuximab

(sɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat cancer
References in periodicals archive ?
Contract award notice: Pnsp 82/2017, Procurement of drugs: Cetuximab, Interferon beta 1-a
M2 PHARMA-January 24, 2018-Combination of Encorafenib, Binimetinib and Cetuximab Demonstrate 48% Confirmed ORR in BRAF-Mutant Colorectal Cancer
Mr Williams, from Bangor, who died on May 30 after a lengthy battle with cancer, was forced to move to England to access bowel cancer drug Cetuximab, which was predicted to increase his chance of full recovery and at the very least double his life expectancy.
Cetuximab will be available as an option for the first-line treatment of patients with certain types of colorectal cancer following a positive recommendation by the All Wales Medicines Strategy Group (AWMSG).
A drug known as Cetuximab will be available as an option for the first-line treatment of patients with certain types of bowel cancer - after a recommendation by the All Wales Medicines Strategy Group (AWMSG).
Two available anti epidermal growth factor receptor monoclonal antibodies are cetuximab and panitumumab which have been approved for metastatic colorectal cancer treatment.
Cetuximab is a chimeric mab targeting ErbB1, with a 10-fold greater affinity compared to its physiological ligands [11].
Although early clinical development of cetuximab was predicated on the hypothesis that tumoral EGFR protein expression would predict treatment benefit (based on preclinical observations and the clinical precedent established by other targeted agents), subsequent analysis of clinical data demonstrated no clear association between EGFR expression and response to cetuximab in mCRC.
Maureen Fleming's doctor told her cetuximab could prolong her life as she battles bowel cancer.
Earlier this year, health chiefs in North Wales told Yvonne Briscoe she would not be allowed to take Cetuximab, a drug which can shrink tumours, because she was not an "exceptional case".
Cetuximab is effective in many patients with colorectal cancer or squamous cell cancer of the head and neck, but the benefits rarely last longer than a year, and for some patients it has no effect at all.
We know that smart drugs like Cetuximab are not always effective in the cancer cells they're supposed to target because there are no positive predictive markers for selecting the patients who will benefit from treatment with EGFR-targeted therapies, including EGFR itself," said lead author Nita Maihle, professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences and of Pathology at Yale School of Medicine.